Crossmark

Multiomic quantification of the KRAS mutation dosage improves the preoperative prediction of survival and recurrence in patients with pancreatic ductal adenocarcinoma

Crossref DOI link: https://doi.org/10.1038/s12276-024-01382-0

Published Online: 2025-01-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yun, Won-Gun

Kim, Daeun

Han, Youngmin

Kwon, Wooil

Lee, Seong-Geun

Jang, Jin-Young

Park, Daechan https://orcid.org/0000-0003-4991-5247
Funding

Funding for this research was provided by:

National Research Foundation of Korea (RS-2024-00341899)

National Research Foundation of Korea (RS-2023-00285390)

National Research Foundation of Korea (2022R1A2C2011122)
License Information

Text and Data Mining valid from 2025-01-08

Version of Record valid from 2025-01-08
More Information

Article History

Received: 13 November 2023

Revised: 29 August 2024

Accepted: 25 October 2024

First Online: 8 January 2025

Competing interests

: The authors declare no competing interests.

: This study was approved by the Institutional Review Board of Seoul National University Hospital (H-1705-031-852) and conducted in compliance with the 1975 Declaration of Helsinki and its later versions. All samples used in this study were obtained with written informed consent, but participants were not compensated.

Document is current

Any future updates will be listed below